Suppr超能文献

GOLDIC疗法有望成为一种组织生物制剂:文献系统综述

GOLDIC Therapy Holds Promise as an Orthobiologic Agent: A Systematic Review of the Literature.

作者信息

Jeyaraman Madhan, Packkyarathinam R P, Thangaraju Thamizhmathi, Jeyaraman Naveen, Chellamuthu Girinivasan, Khanna Manish

机构信息

Department of Orthopaedics, ACS Medical College and Hospital, Dr MGR Educational and Research Institute, Chennai, Tamil Nadu India.

Virginia Tech India, Dr MGR Educational and Research Institute, Chennai, Tamil Nadu India.

出版信息

Indian J Orthop. 2024 May 7;58(7):858-865. doi: 10.1007/s43465-024-01167-7. eCollection 2024 Jul.

Abstract

INTRODUCTION

Orthobiologic agents play a significant role in regenerative medicine. The quest for newer and more effective Orthobiologic agents is never-ending, leading to the evolution of more reformed products. GOLDIC (GOLD Induced cytokine) is a recently evolving Orthobiologic agent developed by conditioning autologous serum with gold particles. We aim to collate the available evidence on GOLDIC and provide a systematic literature review.

MATERIALS AND METHODS

Using Cochrane and PRISMA guidelines literature search was done for GOLDIC. After duplicate removal and exclusions, 62 articles were scrutinized, of which 8 articles qualified for full-text review. A risk-of-bias assessment of the included studies was done.

RESULTS

All articles showed standardized preparation methods of GOLDIC and uniformity in the number of doses administered, except one study. Reproducible results were noted like an increase in plasma gelsolin and improved KOOS, WOMAC, and VAS scores.

CONCLUSION

GOLDIC has the potential to be a significant Orthobiologic modality considering its standardized preparation techniques, method of administration, and uniformly reproducible outcome measures. However, further high-quality evidence is needed to analyze the clinical efficiency and safety profile of GOLDIC.

SYSTEMATIC REVIEW REGISTRATION

INPLASY202350027 [https://doi.org/10.37766/inplasy2023.5.0027].

摘要

引言

生物制剂在再生医学中发挥着重要作用。对更新、更有效的生物制剂的探索永无止境,这导致了更多改良产品的出现。GOLDIC(金诱导细胞因子)是一种最近研发的生物制剂,通过用金颗粒处理自体血清而制成。我们旨在整理关于GOLDIC的现有证据,并进行系统的文献综述。

材料与方法

根据Cochrane和PRISMA指南对GOLDIC进行文献检索。在去除重复文献和排除无关文献后,对62篇文章进行了筛选,其中8篇文章符合全文审查标准。对纳入研究进行了偏倚风险评估。

结果

除一项研究外,所有文章均显示了GOLDIC的标准化制备方法以及给药剂量的一致性。观察到了可重复的结果,如血浆凝溶胶蛋白增加以及KOOS、WOMAC和VAS评分改善。

结论

考虑到GOLDIC的标准化制备技术、给药方法和一致可重复的结果测量,它有潜力成为一种重要的生物治疗方式。然而,需要进一步的高质量证据来分析GOLDIC的临床疗效和安全性。

系统评价注册

INPLASY202350027 [https://doi.org/10.37766/inplasy2023.5.0027]

相似文献

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验